Allogene Therapeutics, Inc.
NASDAQ:ALLOBiotechnology
+$0.02 today
- Market cap
- $241.11M
- Beta
- 0.46
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$0.72
Volume 10.55M
Average 10.19M
ALLO Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Allogene Therapeutics, Inc.NASDAQ: ALLO
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses declines year over year
Q1 FY2026 other income / expenses of $3.49M fell 36.1% year over year, behind the -3.2% change in trailing-twelve-month other income / expenses. Sequentially, it fell 3.0% from the prior quarter.
Context
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -36.1% toward the trailing-twelve-month pace of -3.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 16.05M USD
- Year-over-year change
- -0.0%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.05M | -0.0% |
| FY2024 | 2024-12-31 | 16.05M | +3300.8% |
| FY2023 | 2023-12-31 | 472K | +109.7% |
| FY2022 | 2022-12-31 | (4.88M) | -162.4% |
| FY2021 | 2021-12-31 | (1.86M) | — |
Other Income / Expenses vs competitors
How ALLO compares with its peers on the latest reported figures
- ALLO's LTM Mar 2026 other income / expenses of $16.46M is the highest of the 9 companies compared; the peer median is -$4.25M.
- Its year-over-year change of -3.2% is the highest of 9, against a peer median of -86.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.46M | -3.2% | — | — | |
| LTM Mar 2026 | $9.52M | -61.3% | -24.7% | 150.7% | |
| LTM Mar 2026 | $9.09M | -27.2% | +21.7% | — | |
| LTM Mar 2026 | -$2.06M | -113.1% | — | 18.4% | |
| LTM Mar 2026 | -$3.13M | -36.7% | — | 13.5% | |
| LTM Mar 2026 | -$5.37M | -124.3% | — | 11.9% | |
| LTM Mar 2026 | -$23.45M | -215.6% | — | 34.4% | |
| LTM Mar 2026 | -$23.51M | -111.8% | — | 25.4% | |
| LTM Dec 2025 | -$30.41M | -55.7% | — | 114.5% | |
| Peer median (excluding ALLO) | -$4.25M | -86.5% | -1.5% | 25.4% | |
Competitors are the stored peer set for ALLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 114.09M | 156K | 95K | 22K | 0 |
| Cost of Revenue | 0 | 14.3M | 0 | 0 | 12.36M |
| Gross Profit | 114.09M | (14.14M) | 95K | 22K | (12.36M) |
| Gross Margin | 100.0% | -9063.5% | 100.0% | 100.0% | — |
| Research & Development | 220.18M | 256.39M | 242.91M | 192.3M | 150.15M |
| Selling, General & Admin | 74.11M | 79.31M | 71.67M | 65.21M | 56.78M |
| Operating Expenses | 294.28M | 321.4M | 327.83M | 273.22M | 194.57M |
| Depreciation & Amortization | 10.45M | 14.3M | 14.2M | 13.64M | 12.36M |
| EBITDA | (171.6M) | (326.12M) | (313.07M) | (243.33M) | (177.45M) |
| EBITDA Margin | -150.4% | -209050.6% | -329543.2% | -1106031.8% | — |
| Operating Income | (180.19M) | (335.54M) | (327.74M) | (273.2M) | (206.93M) |
| Operating Margin | -157.9% | -215087.2% | -344986.3% | -1241813.6% | — |
| Interest Income | 1.71M | 4.57M | 18.31M | 20.15M | 19.29M |
| Interest Expense | 0 | 0 | 0 | 181K | 1.08M |
| Other Income / Expenses | (1.86M) | (4.88M) | 472K | 16.05M | 16.05M |
| Income Before Tax | (182.05M) | (340.41M) | (327.27M) | (257.15M) | (190.89M) |
| Pre-Tax Margin | -159.6% | -218214.1% | -344489.5% | -1168850.0% | — |
| Income Tax Expense | 0 | 0 | 0 | 443K | 0 |
| Net Income | (182.05M) | (340.41M) | (327.27M) | (257.59M) | (190.89M) |
| Net Margin | -159.6% | -218214.1% | -344489.5% | -1170863.6% | — |
| EPS (Basic) | (1.34) | (2.38) | (2.09) | (1.32) | (0.87) |
| EPS (Diluted) | (1.34) | (2.38) | (2.09) | (1.32) | (0.87) |
| Weighted Avg Shares | 135.82M | 143.15M | 156.93M | 194.81M | 220.62M |
| Weighted Avg Shares (Diluted) | 135.82M | 143.15M | 156.93M | 194.81M | 220.62M |
Allogene Therapeutics, Inc.
NASDAQ:ALLO
Intrinsic Alpha fair value
Locked
Current Price
$0.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.